Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Other financing activities (2016 - 2025)

iBio (IBIO) has disclosed Other financing activities for 12 consecutive years, with -$46.3 million as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to -$46.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2025, up 4417.28% year-over-year, with the annual reading at $6.2 million for FY2025, 6997.73% up from the prior year.
  • Other financing activities for Q4 2025 was -$46.3 million at iBio, down from $50.0 million in the prior quarter.
  • The five-year high for Other financing activities was $50.0 million in Q3 2025, with the low at -$46.3 million in Q4 2025.
  • Average Other financing activities over 5 years is $421333.3, with a median of $12000.0 recorded in 2022.
  • The sharpest move saw Other financing activities tumbled 100.55% in 2021, then skyrocketed 485.71% in 2024.
  • Over 5 years, Other financing activities stood at -$17000.0 in 2021, then soared by 170.59% to $12000.0 in 2022, then plummeted by 775.0% to -$81000.0 in 2023, then soared by 200.0% to $81000.0 in 2024, then plummeted by 57318.52% to -$46.3 million in 2025.
  • According to Business Quant data, Other financing activities over the past three periods came in at -$46.3 million, $50.0 million, and $81000.0 for Q4 2025, Q3 2025, and Q2 2024 respectively.